Literature DB >> 8943852

Mechanism and effects of the binding of lupus anticoagulant IgG and prothrombin to surface phospholipid.

L V Rao1, A D Hoang, S I Rapaport.   

Abstract

We report here experiments on how lupus anticoagulant antibodies (LA IgG) that react with prothrombin bind to surface phospholipid and affect prothrombin's affinity for surface phospholipid and activation to thrombin. LA IgG was purified by protein A chromatography from the plasma of 16 patients of whom four had associated hypoprothrombinemia and 10 had experienced thrombosis. Many LA IgG bound, in the absence of phospholipid and calcium, not only to immobilized prothrombin but to both prothrombin 1 and fragment 1, which established at least an oligoclonal origin of LA IgG. No LA IgG bound to thrombin. Although prothrombin and Ca2+ were required to support binding of LA IgG to immobilized phosphatidylserine (PS), prothrombin at higher concentrations inhibited binding, presumably by competing with prothrombin/LA IgG complexes for PS binding sites. Prothrombin 1, which cannot bind to PS, also inhibited binding of many LA IgG to PS, presumably by forming competing soluble prothrombin 1/LA IgG complexes. Despite their ability to react with prothrombin independent of phospholipid, LA IgG enhanced binding of prothrombin to immobilized phospholipid and to cultured human umbilical vein endothelial cells. Prothrombin bound with LA IgG to the surface of endothelial cell monolayers could be activated to thrombin after supernatant prothrombin and LA IgG were washed away. The relation is discussed of these observations to a hypothesis that LA IgG mediated concentration of prothrombin on cell surface phospholipid represents a mechanism by which LA IgG could increase thrombotic risk.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8943852

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Binding properties of antibodies to prothrombin and beta2-glycoprotein I (beta2-GPI) assayed by ELISA and dot blot.

Authors:  R R Forastiero; M E Martinuzzo; L O Carreras
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

2.  New tests to detect antiphospholipid antibodies: antiprothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies.

Authors:  Savino Sciascia; Munther A Khamashta; Maria Laura Bertolaccini
Journal:  Curr Rheumatol Rep       Date:  2014-05       Impact factor: 4.592

Review 3.  Anti-phospholipid antibodies (aPL) and apoptosis: prothrombin-dependent aPL as a paradigm for phospholipid-dependent interactions with apoptotic cells.

Authors:  Joyce Rauch; Paolo D'Agnillo; Rebecca Subang; Jerrold S Levine
Journal:  Thromb Res       Date:  2004       Impact factor: 3.944

4.  Lupus anticoagulants in two children--bleeding due to nonphospholipid-dependent antiprothrombin antibodies.

Authors:  Karin Knobe; Ulf Tedgård; Torben Ek; Per-Erik Sandström; Andreas Hillarp
Journal:  Eur J Pediatr       Date:  2012-04-19       Impact factor: 3.183

Review 5.  Antiphospholipid antibodies and platelets.

Authors:  A De Jong; V Ziboh; D Robbins
Journal:  Curr Rheumatol Rep       Date:  2000-06       Impact factor: 4.592

Review 6.  Antibodies to serine proteases in the antiphospholipid syndrome.

Authors:  Pojen P Chen; Ian Giles
Journal:  Curr Rheumatol Rep       Date:  2010-02       Impact factor: 4.592

7.  Discovery and characterization of 2 novel subpopulations of aPS/PT antibodies in patients at high risk of thrombosis.

Authors:  Mathivanan Chinnaraj; William Planer; Vittorio Pengo; Nicola Pozzi
Journal:  Blood Adv       Date:  2019-06-11

8.  Ischemic Stroke: An Underestimated Complication of COVID-19.

Authors:  Wen Cao; Cong Zhang; Huan Wang; Qianqian Wu; Yujia Yuan; Junmin Chen; Shuo Geng; Xiangjian Zhang
Journal:  Aging Dis       Date:  2021-06-01       Impact factor: 6.745

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.